Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Balixafortide

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Spexis announces promising pre-clinical data with balixafortide in combination
    Spexis announces promising pre-clinical data with balixafortide in combination

    13 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/12/13/2572358/0/en/Spexis-announces-promising-pre-clinical-data-with-balixafortide-in-combination-with-various-therapies-on-the-market-for-treating-B-cell-lymphomas.html

    GLOBENEWSWIRE
    13 Dec 2022
    Share Share
    Spexis announces promising data with balixafortide with various therapies
    Spexis announces promising data with balixafortide with various therapies

    13 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/12/13/2572358/0/en/Spexis-announces-promising-pre-clinical-data-with-balixafortide-in-combination-with-various-therapies-on-the-market-for-treating-B-cell-lymphomas.html

    GLOBENEWSWIRE
    13 Dec 2022
    Share Share
    Spexis announces positive renal impairment trial results with balixafortide
    Spexis announces positive renal impairment trial results with balixafortide

    22 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/22/2520691/0/en/Spexis-announces-positive-renal-impairment-clinical-trial-results-with-balixafortide.html

    GLOBENEWSWIRE
    22 Sep 2022
    Share Share
    Polyphor provides update on the future of the FORTRESS study of balixafortide
    Polyphor provides update on the future of the FORTRESS study of balixafortide

    19 Jul 2021

    // BLOOMBERG

    https://www.bloomberg.com/press-releases/2021-07-16/eqs-adhoc-polyphor-provides-update-on-the-future-of-the-fortress-study-of-balixafortide-and-announces-initial-restructuring

    BLOOMBERG
    19 Jul 2021
    Share Share
    Polyphor flops a phase 3, jeopardizing its future
    Polyphor flops a phase 3, jeopardizing its future

    28 Jun 2021

    // FIERCEBIOTECH

    https://www.fiercebiotech.com/biotech/polyphor-flops-a-phase-3-jeopardizing-its-future-as-shares-more-than-halved

    FIERCEBIOTECH
    28 Jun 2021
    Share Share
    Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide
    Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide

    28 Jun 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/06/28/2253544/0/en/Polyphor-Provides-Update-on-the-Phase-III-FORTRESS-Study-of-Balixafortide-in-Patients-With-Advanced-HER2-Negative-Breast-Cancer.html

    GLOBENEWSWIRE
    28 Jun 2021
    Share Share